Abstract
The amyloid-β (Aβ) peptide is the principal components of the senile plaques found in the brains of patients with Alzheimers disease (AD). The poorly soluble 40-42 amino acid peptide, formed from the cleavage of the Ab precursor protein (APP) by two proteases, is believed to play a central role in the pathogenesis of AD. β-Secretase (memapsin 2, BACE1), a membrane-anchored aspartic protease, is responsible for the initial step of APP cleavage leading to the generation of Aβ. Identification and structural determination of β-secretase have established it to be a primary drug target for AD therapy and stimulated active studies on the inhibitors of this protease. Here we review more recent developments in the design and testing of structure-based β-secretase inhibitors.
Keywords: Alzheimer's disease, amyloid-β peptide, β-amyloid precursor protein, β-Secretase, Memapsin 2, aspartyl protease inhibitors, BACE-1, neurodegenerative disease, drug development
Current Topics in Medicinal Chemistry
Title: Recent Developments of Structure Based β-Secretase Inhibitors for Alzheimers Disease
Volume: 5 Issue: 16
Author(s): Aurn K. Ghosh, Nagaswamy Kumaragurubaran and Jordan Tang
Affiliation:
Keywords: Alzheimer's disease, amyloid-β peptide, β-amyloid precursor protein, β-Secretase, Memapsin 2, aspartyl protease inhibitors, BACE-1, neurodegenerative disease, drug development
Abstract: The amyloid-β (Aβ) peptide is the principal components of the senile plaques found in the brains of patients with Alzheimers disease (AD). The poorly soluble 40-42 amino acid peptide, formed from the cleavage of the Ab precursor protein (APP) by two proteases, is believed to play a central role in the pathogenesis of AD. β-Secretase (memapsin 2, BACE1), a membrane-anchored aspartic protease, is responsible for the initial step of APP cleavage leading to the generation of Aβ. Identification and structural determination of β-secretase have established it to be a primary drug target for AD therapy and stimulated active studies on the inhibitors of this protease. Here we review more recent developments in the design and testing of structure-based β-secretase inhibitors.
Export Options
About this article
Cite this article as:
Ghosh K. Aurn, Kumaragurubaran Nagaswamy and Tang Jordan, Recent Developments of Structure Based β-Secretase Inhibitors for Alzheimers Disease, Current Topics in Medicinal Chemistry 2005; 5 (16) . https://dx.doi.org/10.2174/156802605775009711
DOI https://dx.doi.org/10.2174/156802605775009711 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metal-Protein Attenuating Compounds (MPACs) for the Treatment of Alzheimers Disease
Drug Design Reviews - Online (Discontinued) Chemotherapy Resistance in Breast Cancer
Current Cancer Therapy Reviews Multiple Faceted Roles of Cocaine in Potentiation of HAND
Current HIV Research Memory Impairment is Associated with Serum Methylarginines in Older Adults
Current Alzheimer Research Angina in Women without Obstructive Coronary Artery Disease
Current Cardiology Reviews Targeting the Nrf2-Heme Oxygenase-1 Axis after Intracerebral Hemorrhage
Current Pharmaceutical Design Understanding Crime in Schizophrenia - Risk Factors and Prevention Review
Current Psychiatry Reviews Human-Derived Organ-on-a-Chip for Personalized Drug Development
Current Pharmaceutical Design Lower Uric Acid Linked with Cognitive Dysfunction in the Elderly
CNS & Neurological Disorders - Drug Targets Network Building of Proteins in a Biochemical Pathway: A Computational Biology Related Model for Target Discovery and Drug-Design
Current Bioinformatics Memantine: A Therapeutic Approach in Treating Alzheimers and Vascular Dementia
Current Drug Targets - CNS & Neurological Disorders Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Current Pharmaceutical Design Chinese Herbal Medicine Interventions in Neurological Disorder Therapeutics by Regulating Glutamate Signaling
Current Neuropharmacology Mind-Body Therapies and Osteoarthritis of the Knee
Current Rheumatology Reviews Bigger Influence by Smaller Particles in Tactile-Visual Cross-Modal Roughness Perception of Fine Surface
Neuroscience and Biomedical Engineering (Discontinued) Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease
Current Drug Metabolism Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets COX-2 Enzyme and its Inhibitors
Current Bioactive Compounds Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews An Efficient One-Step Synthesis of 1H-pyrazolo[3,4-b]pyridines in Basic Ionic Liquid [bmim]OH
Letters in Organic Chemistry